Inloggad som:
HARMONi-3 (SMT112-3003)
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
HARMONi-3 (SMT112-3003)
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2025-06-16)